metaPreg - Antithyroid drugs during pregnancy

Antithyroid drugs

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.23 [1.09, 1.38]	20%	13 studies	250,165	20,031	probable	ROB
Major congenital malformations	1.30 [0.94, 1.79]	0%	7 studies	268	3,483	not evaluable	ROB
Urinary malformations	1.69 [1.10, 2.61]	58%	3 studies	17,729	15,800	not evaluable	ROB
Genital anomalies	1.17 [0.96, 1.41]	0%	3 studies	25,848	15,800	not evaluable	ROB
Limb defects	1.08 [0.82, 1.41]	61%	3 studies	74,800	15,800	not evaluable	ROB
Respiratory system anomalies	1.16 [0.67, 2.01]	71%	3 studies	16,037	15,800	not evaluable	ROB
Congenital heart defects	1.33 [0.98, 1.79]	71%	3 studies	77,713	15,800	not evaluable	ROB
Ear, face and neck anomalies	1.50 [0.59, 3.82]	0%	2 studies	917	2,909	not evaluable	ROB
Eye defects	1.39 [0.70, 2.74]	0%	2 studies	2,493	2,909	not evaluable	ROB
Severe congenital heart defect	0.63 [0.04, 9.47]	71%	2 studies	739	2,757	not evaluable	ROB
Abdominal wall defects	3.37 [1.63, 6.96]	0%	2 studies	933	2,909	not evaluable	ROB
Ano-rectal atresia and stenosis	1.41 [0.29, 6.91]	46%	3 studies	1,057	3,208	not evaluable	ROB
Cardiac septal defects	1.87 [1.14, 3.06]	-	1 study		1,097	not evaluable	ROB
Craniosynostosis	1.53 [0.43, 5.51]	0%	3 studies	1,537	2,684	not evaluable	ROB
Digestive system anomalies	1.36 [1.08, 1.71]	0%	2 studies	12,070	13,337	not evaluable	ROB
Nervous system anomalies	1.45 [1.06, 2.00]	0%	2 studies	5,884	13,337	not evaluable	ROB
Omphalocele	3.02 [0.56, 16.34]	66%	3 studies	165	3,321	not evaluable	ROB
Syndromes and chromosomal abnormalities	0.88 [0.34, 2.27]	26%	2 studies	5,557	2,909	not evaluable	ROB
Aortic valve atresia/stenosis	1.75 [0.07, 44.39]	71%	2 studies	494	2,643	not evaluable	ROB
Atresia of bile ducts	0.48 [0.06, 3.92]	0%	2 studies	3	3,194	not evaluable	ROB
Carbimazole embryopathy	5.24 [0.80, 34.53]	50%	2 studies	2,048	13,095	not evaluable	ROB
Choanal atresia	12.25 [5.02, 29.88]	0%	2 studies	119	139	not evaluable	ROB
Congenital hydronephrosis	2.60 [0.62, 10.95]	0%	2 studies	10	3,194	not evaluable	ROB
Hypospadias	1.85 [0.27, 12.64]	0%	2 studies	4	3,194	not evaluable	ROB
Oro-facial clefts	1.22 [0.78, 1.90]	0%	2 studies	3,467	13,455	not evaluable	ROB
Pulmonary valve stenosis	1.72 [0.45, 6.64]	0%	2 studies	1,519	577	not evaluable	ROB
Situs inversus	16.80 [2.99, 94.32]	35%	2 studies	27	2,757	not evaluable	ROB
Ventricular septal defect	0.99 [0.51, 1.91]	0%	2 studies	37	3,194	not evaluable	ROB
Coarctation of aorta	3.99 [1.02, 15.54]	-	1 study	1,137	14	not evaluable	ROB
Microcephaly / Small head circumference for gestational age	-	-	0 study
26 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Preterm (< 37 weeks)	0.95 [0.78, 1.16]	3%	11 studies	639	2,427	low	ROB
Low birth weight (< 2500g)	1.34 [0.78, 2.32]	55%	4 studies	307	1,324	not evaluable	ROB
Small for gestational age (weight)	1.06 [0.86, 1.30]	0%	3 studies	560	1,400	not evaluable	ROB
Small for gestational age (length)	-	-	0 study
2 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Maternal liver disorder / failure during pregnancy	-	-	0 study
Preeclampsia	0.54 [0.13, 2.21]	0%	3 studies	11	362	not evaluable	ROB
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Goiter	2.03 [0.18, 23.21]	57%	3 studies	27	170	not evaluable	ROB
Hypothyroidism (fetal/neonatal)	2.54 [0.51, 12.61]	6%	4 studies	11	346	not evaluable	ROB
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)	3.27 [0.40, 26.43]	40%	3 studies	15	204	not evaluable	ROB
Hearing loss / Auditory deficit	0.56 [0.08, 3.80]	5%	2 studies	5	3,194	not evaluable	ROB
Neonatal hyperthyrotropinemia	3.02 [1.04, 8.78]	-	1 study	18	111	not evaluable	ROB
2 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Child/Infant death (> 28 days of life)	-	-	0 study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Early intrauterine death (< 22 weeks)	1.89 [0.68, 5.24]	85%	4 studies	580	3,399	not evaluable	ROB
Intrauterine deaths (as a whole or unspecified)	1.41 [0.88, 2.25]	0%	5 studies	86	435	not evaluable	ROB
Elective/induced termination of pregnancy	1.97 [1.17, 3.33]	0%	3 studies	99	3,295	not evaluable	ROB
Late intrauterine deaths (> 22 weeks)	0.20 [0.01, 6.47]	74%	2 studies	9	167	not evaluable	ROB
Perinatal death	0.76 [0.36, 1.56]	0%	3 studies	29	3,350	not evaluable	ROB
Ectopic pregnancy	-	-	0 study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Neuro-developmental disorders (as a whole)	5.34 [2.17, 13.10]	-	1 study	692	20	not evaluable	ROB